Shares in the USA-based biotech firm OncoGenex Pharmaceuticals (Nasdaq: OGXI) gained more than 50% in pre-market trading, following the announcement of a reverse merger with the privately held pharmaceutical company Achieve Life Science.
The proposed all-stock deal will see Achieve acquired by OncoGenex. Equity holders in the former will own 75% of the new company, the latter 25%.
Following completion of the merger, OncoGenex will be renamed Achieve Life Sciences Inc.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze